OMEGA

OMEGA Investment Co., Ltd. (hereinafter referred to as "the Company") does not guarantee the authenticity or interpretation of the data described on this website, both expressly and implicitly. We are not responsible for any damage caused by the information on this website... Fine modality focusing on iPS cells, which could lead to interesting growth in regenerative therapy market. Aims at positive profitability by FY3/2024 by growing clinical iPS cell and clinical testing. The company's iPS cells are compliant with regulations in Japan, the US and Europe, and are able to be used globally. The management estimates that stemchymal for spinocerebellar degeneration alone could generate revenue of 19 billion yen. The pipeline is short on items... Cancer and leukemia markets attractive but competitive. A unique new drug creation by "module technology', which utilises off-patent ingredients of existing drugs. Hence, faster development at lower risk. In return it makes the company biased..

Primary location: Tokyo Japan